US Bankruptcy Chapter 11 Insolvency SEC Filings — June 23, 2026

Emerged from Chapter 11 with COD income first reducing NOLs dollar-for-dollar, creating potential for future tax-free income if NOL shield remains intact—but subject to IRS challenge under Section 382.

Ownership change triggered a Net Unrealized Built-In Loss (NUBIL) because asset tax basis far exceeded market value at emergence. This could generate future tax deductions, boosting cash flow against future taxable income.

Stalking horse bid from Eli Lilly ($50M for STAC-BBB capsid and ZFP tech) and Astellas ($25M upfront + up to $25M milestones for Fabry gene therapy) validates significant asset value despite bankruptcy—implies IP may fetch $75M+ in sale.

DIP facility of $30M (initial draw $10.5M) from Northridge ATM provides near-term liquidity to fund operations through sale process, reducing risk of disorderly liquidation.

Company expects to continue historic real estate leasing business for at least two years, suggesting operational continuity post-bankruptcy—potential for turnaround if leasing market improves.

Nasdaq delisting and OTCQB trading (since May 5, 2026) signals severe equity impairment—current shareholders face near-total dilution or wipeout in asset sale.

Aggregate value of shares, warrants, and debt issued was materially less than liabilities extinguished—implies existing shareholders received de minimis consideration, severely diluting pre-petition equity.

Chapter 11 filing with stalking horse bids suggests a sale process is underway—likely no recovery for common equity beyond pennies on dollar.

IRS may challenge the exception to Section 382 limitations—risk of NOL cap and tax liability that could impair REIT qualification and shareholder distributions.

Milestone payments ($25M) tied to Fabry asset sale are contingent on FDA/regulatory success—highly uncertain given gene therapy development risk.

Ownership change creates Section 382 risk—net unrealized built-in loss (NUBIL) may limit future NOL utilization, increasing tax burden and potentially jeopardizing REIT status. Pending IRS stance.

Massive cancellation of debt income will first reduce NOLs, then asset basis—may leave company with minimal tax attributes to offset future taxable income, increasing cash tax payments.

Reorganization creates tax uncertainties that could threaten REIT qualification—loss of REIT status would result in corporate-level tax, potentially eliminating dividends.

DIP facility ($30M) with initial draw ($10.5M) may not be sufficient to fund operations through a contested sale process—risk of cash crunch if bankruptcy proceedings extend beyond 6-12 months.

Stalking horse bid of $75M+ may undervalue certain assets (e.g., Fabry program) if higher bidders emerge; conversely, no higher bid could indicate limited buyer interest.

REIT sector weakness (rising interest rates, office space demand decline) may persist, limiting OPIRQ's ability to lease space and generate stable cash flow post-emergence.

Isaralgagene civaparvovec (Fabry candidate) faces clinical and regulatory risk—milestones and value depend on FDA approval, currently uncertain.

Absence of insider trading activity in filings suggests management may be disengaged or restricted—lack of buying signals in new equity raises concerns about confidence in post-emergence plan.

Shift to OTCQB limits institutional access, liquidity, and price transparency—further depresses any residual equity value for common holders.

If IRS permits Section 382 exception, OPIRQ will carry forward sizable NOLs that can shield future income for years—potential for tax-free cash generation if leasing operations stabilize.

Company may elect to reduce depreciable asset basis and accelerate depreciation deductions, increasing cash flow and improving distributable income if REIT qualification maintained.

Eli Lilly gains STAC-BBB capsid platform (next-gen CNS delivery) at ~$50M discount to biotech M&A norms; Astellas secures Fabry gene therapy with modest upfront—indicating potential for recovery of higher bids in bankruptcy auction.

Unsecured creditors may trade at deep discount—if sale yields proceeds above expectations (e.g., $100M+), these claims could see significant recovery.

Post-emergence debt and equity instruments may trade at discounts to intrinsic value given tax uncertainty—sharp investors can exploit mispricing between convertible securities and common equity.

If interest rates decline in 2026-27, OPIRQ's real estate portfolio could revalue upward, benefiting post-bankruptcy equity and bond holders.

The $30M DIP facility (L+500-800 bps, if typical) offers yield pickup for short-dated bankruptcy financing, secured by super-priority claims.

Pre-petition shareholders may challenge valuation in bankruptcy—if plan is overturned or modified, equity could see recovery.

Investors with risk appetite can speculate on Fabry milestones—if isaralgagene civaparvovec succeeds, Astellas may owe $25M, boosting recovery for some stakeholders.

Both filings show companies using Chapter 11 to separate ongoing operations (OPIRQ) from monetizing crown jewels (Sangamo)—suggesting bankruptcy is increasingly a tool for value maximization, not just liquidation.

OPIRQ's COD income/NOL mechanics highlight how bankrupt firms can preserve or monetize tax attributes to benefit post-reorganization entities. Investors should monitor NOL valuation as a recovery variable in large-capex sectors.

Sangamo's stalking horse deals with Big Pharma (Lilly, Astellas) at deep discounts reflect a sector trend of distressed biotechs liquidating IP to survive—creating acquisition opportunities for well-capitalized buyers to acquire platforms at pennies on the dollar.

OPIRQ's emergence from Chapter 11 amid office real estate downturn signals that the 'work-from-home' structural shift continues to pressure office REITs. Investors should watch for other office REITs (e.g., SL Green, Boston Properties) potentially facing similar stress if lease renewals weaken.

Neither filing revealed insider trading activity—typical for bankrupt companies where management is disincentivized or restricted from trading. This absence of insider buying signals weak confidence in post-emergence equity value.

Sangamo's $30M DIP from a single lender (Northridge ATM) contrasts with traditional bank syndicate loans—reflecting a trend toward specialty lenders providing emergency liquidity at higher costs (likely L+800-1000 bps unsecured).

Decision expected within 6 months; if exception is granted, NOL utilization preserved; if denied, tax liability spikes. Monitor SEC filings for IRS correspondence.

Initial DIP motion approval expected within 1-2 weeks (late June/early July 2026). Outcome determines liquidity headroom for stalking horse auction. Track docket on court website.

Stalking horse bid deadline and potential competing bids expected within 60-90 days after DIP approval; if higher bids emerge, recovery for creditors improves. Watch for bid deadline announcements in case documents.

Post-emergence leasing volume and occupancy rate in Q3 2026 earnings will test the “two-year continuity” guidance. Sequential date: Q3 2026 earnings call (late October/early November 2026).

Astellas milestone payment ($25M) tied to clinical/regulatory progress; any FDA interaction (IND/Phase I/II) within 12-18 months could trigger payment and boost recovery. Track Astellas pipeline updates.

Post-emergence REIT requires 90% income distribution; watch for declaration of first post-bankruptcy dividend (typically within 90 days of emergence) as signal of free cash flow confidence.

Formation of official committee of unsecured creditors could contest stalking horse valuation—especially if claims exceed $75M. Watch for committee formation announcement.

Monitor office REIT sector ETFs (e.g., IYR, XLRE) for contagion risk—if OPIRQ's emergence fails to stabilize, other office REITs may face similar restructurings.